clinical approach to anticoagulation
TRANSCRIPT
![Page 1: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/1.jpg)
BY: DR. NADEEM AKBARHOUSE OFFICER CARDIOLOGY UNIT
CLINICAL APPROACH TO
ANTICOAGULATION
![Page 2: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/2.jpg)
Is a process which causes bleeding to stop.Has three steps: 1. Reflex Vasoconstriction 2. Primary Hemostasis ( Platelet Activation) 3. Secondary Hemostasis ( Coagulation Cascade)
This process results in the formation of Blood clot.
NORMAL HEMOSTASIS:
![Page 3: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/3.jpg)
![Page 4: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/4.jpg)
The coagulation cascade has two initial pathways which lead to Fibrin formation.
1. INTRINSIC PATHWAY 2. EXTRINSIC PATHWAY
COAGULATION CASCADE
![Page 5: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/5.jpg)
![Page 6: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/6.jpg)
the process of hindering the clotting of blood especially by treatment with an anticoagulant.
INDICATIONS FOR ANTICOAGULANTION:1. Venous Thromboembolism Phenomenon.2. Acute Coronary Syndrome3. Atrial Fibrillation4. TIA/Stroke5. DIC6. Prosthetic Heart Valves7. Vascular Surgeries
ANTICOAGULATION
![Page 7: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/7.jpg)
TYPES OF ANTICOAGULANTS:
1. Injectable Anticoagulants LMWH Unfractionated Heparins
2. Oral Anticoagulants Warfarin New Oral Anticoagulants * Factor Xa inhibitors (Rivaroxaban, Apixaban) * Direct Thrombin inhibitors ( Dabigatran)
![Page 8: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/8.jpg)
ORAL ANTICOAGULANTS
![Page 9: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/9.jpg)
Warfarin is an oral Coumarin anticoagulant.Clinically Warfarin is available in mixture of
two racemic forms: R- and S-Warfarin.S- form has 3-5 times greater potency than R-
Warfarin.
WARFARIN
![Page 10: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/10.jpg)
Warfarin acts by antagonizing the anti-hemorrhagic effects of Vitamin K.
It inhibits hepatic sysnthesis of Vitamin K dependent
Coagulation factors II, VII, IX and X by inhibiting Vitamin K1 -2,3 epoxide reductase enzyme, preventing vitamin K from being reduced to its active form.
MECHANISM OF ACTION
![Page 11: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/11.jpg)
![Page 12: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/12.jpg)
Warfarin bioavailability of nearly 100%.Highly bound to plasma protein , mainly
Albumin.Half life of warfarin is 40 hoursMetabolized by Hepatic P-450 enzyme to
inactive metabolites and excreted through Bile and Kidney.
PHARMAKOKINETIC
![Page 13: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/13.jpg)
An anticoagulation effect generally occurs within 24 hours after warfarin administration.
Peak anticoagulant effect may occur in 24 to 96 hours.
The duration of action of a single dose of racemic warfarin is 2 to 5 days.
ANTICOAGULATION EFFECT
![Page 14: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/14.jpg)
Start with loading dose of 10 mg stat and do INR after 16 hours.
If: INR <1.8 : The 2nd dose is 5 mg given 24 hour
after 1st dose. INR >1.8 : The 2nd dose is just 0.5 mg given 24
hour after 1st dose
WARFARIN DOSAGE
![Page 15: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/15.jpg)
Then repeat INR after 16 hours of 2nd dose.The 3rd dose should be given accordingly
INR 3rd Dose Maintenance dose
<2 10 mg 6 mg 2 5 mg 5.5 mg 2.5 4 mg 4.5 mg 2.9 3 mg 4 mg 3.3 2 mg 3.5 mg 3.6 0.5 mg 3 mg 4.1 0 mg 1-2 mg next
day >4.5 miss 2 doses
![Page 16: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/16.jpg)
Effect of Warfarin is monitored by PT/INR.INR = Patient’s PT in sec ISI Mean Normal PT in secISI= International Sensitivity Index.
WARFARIN MONITORING
![Page 17: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/17.jpg)
![Page 18: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/18.jpg)
Indication INRTreatment of venous thrombosis 2.0–3.0Treatment of pulmonary embolism
2.0–3.0
Prophylaxis of venous thrombosis (high-risk surgery)
2.0–3.0
Prevention of systemic embolism 2.0–3.0 Tissue heart valves 2.0–3.0 AMI (to prevent systemic embolism)†
2.0–3.0
Valvular heart disease 2.0–3.0 Atrial fibrillation 2.0–3.0Bileaflet mechanical valve in aortic position
2.0–3.0
Mechanical prosthetic valves (high risk)
2.5–3.5
Systemic recurrent emboli 2.5–3.5
WARFARIN INDICATIONS ALONG INR
![Page 19: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/19.jpg)
IN NON-BLEEDING PATIENTSIN BLEEDING PATIENTS
WARFARIN DOSE TITRATION
![Page 20: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/20.jpg)
DOSE TITRATION IN NON BLEEDING PATIENTS
TARGET INR2.0-3.0
INR 4.1-8.9INR 3.6- 4.0INR 3.1-3.5 INR >9.0INR <2.0
INCREASE BY 10%
DECREASE BY 0-10%
HOLD 1 DOSE,
DECREASE BY 10%
HOLD 2 DOSES,
DECREASE BY 15%, +/- 2.5mg Vit
K
HOLD 2 DOSES,
DECREASE BY 20%, +/- 2.5mg Vit
K
REPEAT INR IN 2 WEEKS
REPEAT INR IN 1
WEEK
REPEAT INR IN 2
DAYS
REPEAT INR NEXT
DAY
REPEAT INR
WITHIN 1 WEEK
![Page 21: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/21.jpg)
MINOR BLEEDING: STOP WARFARIN 2.5 mg VIT.K P/O CHECCK INR DAILY
MAJOR BLEEDING: STOP WARFARIN INJ. VIT K 5-10 mg IV SLOWLY PROTHROMBIN COMPLEX CONCENTRATE 50
U/kg OR FFP 15ml/kg
DOSE TITRATION IN BLEEDING PATIENTS
![Page 22: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/22.jpg)
H Hypertension -( systolic blood pressure >160 mmHg) (Points: 1 )
A Abnormal renal function ( defined as the presence of chronic dialysis or renal transplantation or serum creatinine 200µmol/L (>~2.3 mg/dL)) (Points: 1 ) Abnormal liver function ( defined as chronic hepatic disease (eg. cirrhosis) or biochemical evidence of significant hepatic derangement (eg. bilirubin >2x upper limit of normal, in association with AST/ALT/ALP >3x uper limit normal) (Points: 1 )
S Stroke (Previous history of stroke) (Points: 1 )
B Bleeding (Major bleeding history (anemia or predisposition to bleeding)) (Points: 1 )
L Labile INRs (refers to unstable/high INRs or poor time in therapeutic range(eg<60%))(Points: 1)E Elderly (age >/= 65) (Points: 1 )
D Drug Therapy (concomitant therapy such as antiplatelet agents, NSAID's) (Points: 1 ) Alcohol intake (consuming 8 or more alcoholic drinks per week) (Points: 1)
ASSESSING BLEEDING RISK IN PATIENTS ON ANTICOAGULANTS: HAS-BLED SCORE
![Page 23: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/23.jpg)
WARFARIN CONTRAINDICATIONS:
![Page 24: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/24.jpg)
WARFARIN INTERACTION
![Page 25: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/25.jpg)
It is new oral anticoagulant.
MECHANISM OF ACTION:It is direct inhibitor of Factor Xa and thus inhibits both Intrinsic and Extrinsic pathways.
INDICATIONS: DVT or PE Treatment DVT Prophylaxis ( orthopadec surgery) Nonvalvular Atrial Fibrillation
RIVAROXABAN
![Page 26: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/26.jpg)
1: DVT or PE 15 mg BD PO for 21 days with food, THEN 20 mg OD PO for 6 months. 2: DVT Prophylaxis ( orthopadec surgery) Knee replacement: 10 mg PO OD for 12 days Hip replacement: 10 mg PO OD for 35 days 3: Nonvalvular Atrial Fibrillation 20 mg/day PO with the evening meal
DOSE OF RIVAROXABAN
![Page 27: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/27.jpg)
MODERATE CKD: 20 mg OD after evening meal
SEVERE CKD: 15 mg OD after evening meal
END STAGE CKD or ON DIALYSIS: NOT RECOMENDED
RIVAROXABAN DOSE IN CKD:
![Page 28: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/28.jpg)
Major adverse efffect is INTERNAL BLEEDING.
It has yet no antidote of rivaroxaban.Possible antidote ANDEXANET ALFA is under
investigation.
REVERSAL OF RIVAROXABAN ANTICOAGULATION
![Page 29: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/29.jpg)
It is also new oral anticoagulant.
MECHANISM OF ACTION:It is direct inhibitor of Thrombin.
INDICATIONS: DVT or PE Treatment DVT Prophylaxis ( orthopadec surgery) Nonvalvular Atrial Fibrillation
DABIGATRAN
![Page 30: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/30.jpg)
1: DVT or PE 150 mg BD PO.2: DVT Prophylaxis ( orthopadec surgery) Hip replacement: 220 mg PO OD for 35 days3: Nonvalvular Atrial Fibrillation 150 mg/bd PO.IN CKD: Severe CKD: 75mg BD END stage CKD: NOT RECOMENDED
DOSAGE OF DABIGATRAN
![Page 31: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/31.jpg)
Idarucizumab is the specific antidote for Dabigatran.
REVERSAL OF DABIGATRAN ANTICOAGULATION:
![Page 32: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/32.jpg)
WARFARIN TO RIVAROXABIN Discontinue Warfarin and Start Rivaroxaban when INR <3.0WARFARIN TO DABIGATRAN Discontinue Warfarin and Start Dabigatran when INR <2.0 RIVAROXABAN TO WARFARIN initiate warfarin and a parenteral anticoagulant 24 hour after discontinuation of rivaroxaban.
CONVERTING BETWEEN ORAL ANTICOAGULANTS
![Page 33: Clinical approach to anticoagulation](https://reader035.vdocument.in/reader035/viewer/2022070512/5889def81a28ab83478b6d43/html5/thumbnails/33.jpg)